Liquidia (LQDA) to Release Earnings on Wednesday

Liquidia (NASDAQ:LQDA) is expected to release its earnings data before the market opens on Wednesday, March 12th. Analysts expect Liquidia to post earnings of ($0.39) per share and revenue of $4.60 million for the quarter.

Liquidia Trading Down 0.3 %

Shares of NASDAQ:LQDA opened at $14.82 on Monday. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99. The company has a market capitalization of $1.25 billion, a PE ratio of -9.09 and a beta of 0.07. The business has a 50 day moving average of $14.30 and a two-hundred day moving average of $11.87.

Analysts Set New Price Targets

LQDA has been the subject of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $25.38.

Insiders Place Their Bets

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the sale, the insider now owns 270,388 shares of the company’s stock, valued at approximately $3,185,170.64. This represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 over the last ninety days. Company insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).